oral semaglutide nejm Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj Oral Semaglutide and Cardiovascular Outcomes (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis

25.07

★★★★☆4.8 (126)

Presented at #ACC25: Among participants with type 2 diabetes and cardiovascular disease, chronic kidney disease, or both, oral semaglutide (14 mg) was associated with a lower risk of cardiovascular events than placebo

27.63

★★★★★4.9 (98)

NEJM: Once-Weekly Semaglutide in Adults with Overweight or Obesity : r/medicine

23.28

★★★★★5.0 (157)

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit

21.85

★★★★★4.7 (84)

My first paper in NEJM ! Two weeks ago the results from PIONEER 6, a cardiovascular outcomes trial examining the safety of oral semaglutide versus placebo, were published in the prestigious New… |

21.26

★★★★★4.9 (203)

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

21.10

★★★★★5.0 (176)

Oral Semaglutide in High-Risk Type 2 Diabetes: Cardiovascular Benefit Confirmed in the SOUL Trial

23.21

★★★★★4.8 (132)